Jephcott Lecture
The Control of Drugs and Therapeutic Freedom by Sir Derrick Dunlop MD FRCP (Edinburgh)
The modern drug problem -I prefer to call it the medicines problem because theword'drug'likethe word 'love' has undertones as well as overtonesis in miniature that of the modern, complicated democracy which seeks the ideal of ordered freedom within the law, with the force of sanctions far in the backgroundin which authority and freedom are blended in due proportion and in which the state and the citizen are complementary to each othera sort of age of Pericles.
Democracy, however, is a very difficult form of government. I do not know why we should expect underdeveloped countries to adopt so easily what has taken us hundreds of years to evolve. It requires constant guarding from slipping in one direction into chaotic licence, possibly due to the relaxation of laws on such things as capital and corporal punishment, gambling, pornography, Sunday observance, homosexuality, abortion and divorce, or in the other into bureaucratic tyranny due to the gradual erosion of certain individual liberties by government action. For example, the law of supply and demand and the devil take the hindmostthe economic rule of the jungle, beloved of Victorian ironmastersis nowadays abhorrent to most of us but, in attempting to mitigate its asperities it is difficult to find another logical alternative short of complete communist state controlthe rule of the ant heapwhich most of us do not like very much either. Between these extremes, reforms and revolutions, no matter how salutary, are bound to be hurtful to some and may sometimes create further problems more formidable than the abuses they have sought to remedy. Thus, the drunken motorcar driver had become such a menace that additional measures were required todealwithhim but their imposition has interfered with our freedom to enjoy with any peace of mind a bottle of wine with a friend at dinner before driving soberly home. In the same way, largely due to a very few doctors who have prescribed potent narcotics and hallucinogenic agents so injudiciously (I do not use a stronger term), addiction to them in Britainat one time so minimal as to be a matter ofalmost incredulous envy in other countrieshas suddenly assumed serious proportions. In consequence, under the 1968 Dangerous Drugs Regulations the legal right to prescribe heroin and cocaine to addictsthough not, curiously enough, morphinehas been taken away from us ordinary doctors and confined to those working in special clinics.
Further, the Safety of Drugs Committee has restricted the supply of LSD to the very few psychiatrists who continue to regard that rather sinister drug as a valuable agent in diagnosis and therapeutics. These are perhaps necessary measures but are possibly the thin edge of the bureaucratic wedge to professional medical freedom. The trouble is that, though we nearly all maintain that freedom is good and restriction bad, when someone else's freedom of action becomes inconvenient we usually clamour for its restrictiona restriction which then seems essential in the public interest and based on the purest of motives. 'The Government must do something about it', we say. Such restrictions may be particularly undesirable when imposed hysterically to meet some crisis. We saw recently in Kenya an example of how unrepresented people might have their liberties invaded when our parliamentary machine lacked the opportunity for reflection and worked under pressure of time.
Modern medicines are such potent weaponslike atomic energy, powerful for good but also powerful for evilthat the responsibility for their safe production and use can no longer be left entirely to the manufacturer and prescriber. Yet it is difficult to know how far government should attempt to control their manufacture and use without undue interference with the advance of therapeutics, the wellbeing of the pharmaceutical industry and the cherished freedom of the doctor to prescribe anythinghe likes for his patient, though it is a little doubtful whether the responsibility we have shown in the use of modern medicines entirely justifies that freedom.
'Any health service which hopes to win the consent of doctors must allay the fear that bureaucratic interference will affect professional freedom and come between the doctor and his patient. There is no alternative to self-government by the medical profession in all matters affecting the content of its academic life. It is for the community to provide the apparatus of medicine for the doctor. It is for him to use it freely in accordance with the standards of the profession and the requirements of his oath.' Who do you think said that? Rather surprisingly it was that remarkable man, Aneurin Bevan.
Attempts at the control of medicines have gone on for a very long time. The earliest efforts were the catalogues of medicines or herbals providing detailed descriptions of poppies and mandragora, of mercury and antimony, of eyes of newts and toes of frogs to help physicians to recognize and use these agents. Though his head might be cut off if the consequences of their administration were dire, the physician was not then summoned under the provisions of any Act. From these early herbals grew the London and Edinburgh Pharmacopoeiasessentially herbals themselves but given authority through their respective Royal Colleges. Then came the British Pharmacopoeia of 1864 with its numerous subsequent editions and now there is an International Pharmacopoeia.
We have come a long way since 1864 in laying down standards to try to ensure the purity and strength of medicines; subsequent Food and Drugs and Therapeutic Substances Acts have provided further legal protection for the public in these respects. There has also been a progressive widening in such control so that nowadays a patient can have at least some confidence that he will be supplied with the same agent whether he purchases it in London, New York, Paris or Tokyo. In more spacious days it sufficed if he always bought his infusion of digitalis leaves from Mistress Ford rather than from her rival, Mistress Page down the street, whose brews might differ from each other like the strength of a cup of tea in different homes.
In addition, as the result of the Cancer and Venereal Disease Acts it is no longer possible for charlatans to delude the public by advertising quack nostrums for the treatment of serious disorders. Lastly, various Acts to control the risk of addiction to potent narcotics and to prevent the counter-sale of certain medicines without a medical prescription have been essential measures. This mass of legislation on medicines undertaken in the last hundred years has been almost entirely salutary. The present responsibilities of government, however, in attempting to ensure their safe and efficacious use are much more complex and difficult.
Though we had been well aware for many years of the toxic nature of many of the medicines we were using, we had been somewhat complacent and ostrich-like regarding them and it took the emotional reaction to the thalidomide disaster to galvanize us out of our somewhat laissez-faire attitude. Following it the Ministers of Health, on the advice of a sub-committee under Lord Cohen of Birkenhead of the Standing Medical Advisory Committee, established the Safety of Drugs Committee in 1963 as an interim measure until the comprehensive legislation on medicines now before Parliament could be enacted. It was odd that, in the somewhat bureaucratic welfare state that Britain had become, the Ministers gave the Committee almost complete independence with its own offices, its own staff and with its own records, kept entirely separate from other official papers; but perhaps not so odd when it is remembered that the Minister of Health at the time was Mr Enoch Powell. The Committee itself consists of eleven part-time scientists and physicians with a permanent staff, paid as civil servants, of six doctorsfour of them recruited from industry, on the principle of turning a poacher into a gamekeeperand two pharmacists.
The Committee does not itself undertake pharmacological tests or clinical trials of medicines: the responsibility for these remains firmly with the manufacturer. The Committee simply weighs the manufacturers' submissions on their tests and lays down certain standards for them. Its remit does not impose upon it responsibility to consider the efficacy or comparative efficacy of medicines except in so far as their safety is concerned. Thus, a high degree of toxicity might well be acceptable in one which stayed the progress of cancer whereas one used for a trivial condition would have to be relatively innocuous. Therefore, the clearance of a medicine for marketing does not imply the Committee's recommendation of it as a therapeutic remedy but only its reasonable safety for its intended purpose.
The Association of the British Pharmaceutical Industry and the Proprietary Association of Great Britain, despite the absence of legal sanctions, promised before the Committee started to function on January 1, 1964, that their members would not submit a new drug for clinical trial or market a new drug against the advice of the Committee. They have loyally observed these agree-
ments.
If there are no legal sanctions there are, of course, some unofficial ones: the Minister, for instance, reports to all practising doctors in the Health Service should a new medicine be marketed without the Committee's approval and doctors would draw their own conclusions. Further, if a medicine which had not been cleared by the Committee gave rise to toxic reactions, neither its manufacturer nor its prescriber would stand in a very favourable position in a Court of Law. These are very formidable sanctions. Nevertheless, I like to think in my ingenuous way that the close co-operation of industry with the Committee has had a more altruistic basis than those to which I have adverted.
A committee with freedom of action, relatively untrammelled by legal niceties, which is not bound by tight procedural rules can often conduct business more expeditiously than official organizations since there is a minimum of paper work. For instance, much of the contact with the applicantsthe requests for amplification or clarificationtakes place in robust but usually good-humoured encounters over the telephone or in informal discussions rather than in official communications. Manufacturers seem to have appreciated this informal, elastic approach which perhaps has done something to ease the introduction of controls, previously unfamiliar in this country. Most submissions ofreally new medicines are cleared within three months of their receipt: there are an average of only about 60 of these in a year but their submissions may run into thousands of pages. Submissions of reformulations of established medicines which do not usually require full toxicity data or clinical trials, are very numerous but are usually cleared within a month of their submission.
Out of approximately 3,360 submissions received since January 1, 1964 (about 300 new drugs and the rest reformulations) only 94 have been reiected though some 324 have not been proceeded with by the manufacturer. Doubtless in the case of some of these latter the manufacturer has been unable to produce the evidence required and has retired from the contest. The small number of rejections might suggest that the somewhat elephantine gestation of the primigravid Committee had only produced a mouse. In practice, however, the rejection of medicines which might otherwise have reached the market is a comparatively minor part of the Committee's function: more important is the persuasion of manufacturers to alter their intentions or to modify their promotional claims and to issue early warnings to doctors when the Committee's adverse-reactions-register shows a medicine to be developing undue or unexpected toxic effects. In addition, the mere existence of the Committee may have tightened up standards. As far as possible it has attempted to solve its problems by voluntary compliance and mutual agreement and this seems to have worked fairly well. It may, therefore, be asked why the Government should seek to effect through legislation what is being accomplished reasonably satisfactorily through the Committee's voluntary arrangements with the pharmaceutical industry. There are, however, many reasons for the new legislation which seeks to encompass far more than the limited functions of the Committee.
(1) Probably the least important of these reasons is to give the Committee legal power, the lack of which has not proved an embarrassment in the past, and the danger is probably slight of the Committee's decisions being flouted by industry in the future.
(2) There is a real need for legislation designed to provide an inspection and licensing system to ensure the best conditions for the manufacture, storage and distribution of medicines. At present there is nothing to prevent a small business being set up in a back street, the products of which may not conform to the specifications filed with the applications or be free from hazards which might be detected by a more competent staff. These hazards comprise not only toxicological risks from the active ingredients, but also their diminished effectiveness due to physical or chemical changes during their defective manufacture or subsequent storage.
(3) There is at present remarkably little effective machinery for the enforcement of the quality control of preparations purporting to comply with British Pharmacopoeia specifications. Now that many 16-year-old patents are expiring on a vast number of branded products introduced in the 1950s, numerous 'standard' preparations of potent, potentially hazardous medicines are coming on the market, often from abroad; new legislation is necessary to ensure their quality control, which is at present lacking. (4) Many believe that before licensing a medicine consideration must be given to its efficacy as well as to its safety and that the present remit of the Committee to consider efficacy only in its relationship to a medicine's safety does not go far enough: efficacy and safety, they say, are inseparable.
(5) The licence of a medicine must not only involve its proper manufacture, safety and efficacy but adequate standards for its advertisement and promotion.
(6) Not only human medicines have to be considered but veterinary ones and medicated animal feeding stuffs as well and, in addition, medical devices such as dressings, needles, implants and so forth.
Regulations to control all this and more already operate in America. It is odd that in that freedom-loving country, the home of big business, they have been much more bureaucratic than we have been in their control of medicines. The 1962 Kefauver-Harris Amendments to the 1938 Federal Food, Drug and Cosmetic Act authorized the Food and Drug Authority (the FDA) to establish by regulation standards for good manufacturing practices and, for the first time, to license new medicines not only for their safety but also for their efficacy. Further, the Amendments called for a retrospective evaluation of all medicines marketed from 1938 onwards. Lastly, the advertising provisions of the Amendments are designed to ensure that promotional literature on medicines tells the whole truth and nothing but the truth. For its colossal task of inspecting and licensing throughout America the manufacture of foods, cosmetics and pesticides, as well as human and veterinary medicines, and for evaluating retrospectively some 3,500 medicines and the validity of the claims made for them, the FDA employs at its headquarters in Washington and 18 district offices a vast secretarial and professional staff.
The energetic and forcible Commissioner of the FDA believes it to be completely irrational to attempt to separate the safety from the efficacy of medicines for no medicine is safe, he says, if it fails to cure a disease for which a cure is available. Thus, it is the duty of the FDA to prevent as far as possible the needless suffering and protraction of illness resulting from the use of ineffective medicines and the squandering of money on unnecessary, even if relatively innocuous, remedies such, for example, as multivitamin preparations. He is frank in maintaining that it is the duty of the FDA to interfere to some extent with medical practice. Doctors must, of course, have the right, once medicines have been cleared for marketing, to prescribe what they think best for their patients but whether a medicine is sufficiently safe and efficacious to be marketed must be decided by Government acting on the advice of experts who are less often wrong than non-experts. It is obvious that among the nearly 8,000 preparations now available there are many that are of limited value, useless, undesirable or even actually harmful. Most doctors see insufficient patients with any one disease to evaluate critically the medicines employed for it and, if the doctor is honest, he must admit that he can only gather impressions about the one he uses. These impressions are largely conditioned by the advertisements of the pharmaceutical industry and the claims of its detail men which are not infrequently so loud, incessant and brash as to jam the channels of communication. Thus, the bewildered physician prescribes by suggestion and seldom from information: it is, therefore, the duty of the FDA to help him by strict supervision of the efficacy as well as the safety of new and old medicines and their accompanying promotional literature.
The Commissioner pours scorn on the suggestion that a gradual process of medical education in these matters may produce in the long run sounder results than the more immediate effect of legal edicts. He says, in so many words, that when the house is on fire a lecture on how to prevent incendiarism is inopportune; what is needed is to put out the fire and only then is it appropriate to give lessons as to how to prevent more fires in the future.
There is a great deal requiring to be done in this country which the FDA already does, often very well, in America. In doing it, however, it is to be hoped that we will avoid the dangers to professional freedom inherent in such agencies as the FDA. Our freedom in this country did not drop down on us like manna from heaven; it is the result of centuries of resistance to the power of the executive.
The drawbacks to the FDA are first, that it is, of course, entirely composed of civil servants and it is questionable whether a professional bureaucracy, not always attracting the best talent, should dogmatize to the medical profession on the safety, efficacy, dosage, indications, contraindications and dangers of therapeutic agents. It may be argued that the pronouncements of the FDA on package inserts and pharmaceutical advertisements are only guide lines and not official directions, just as we have guide lines in our therapeutic publications. Nevertheless, doctors in America are subject to civil actions by patients much more often than they are here and such actions are also far more frequently successful. Consequently they are becoming extremely chary of deviating in their practice from the package inserts of the FDA which are thus tending to have the effect, if not the actuality, of regulations. Secondly, for reasons which I have no time to develop, delay is almost inseparable from the methods adopted by the FDA in licensing medicines for the market. It must be admitted that its notorious procrastination saved America from the consequences of the thalidomide disaster but it can have a detrimental effect on therapeutic research and is most frustrating to the pharmaceutical industry. It is insufficiently appreciated, too, that excessive delay in clearing a valuable medicine for the market may have results as unfortunate as those arising from the clearance of one which is undesirably toxic. Consider, for example, the number of people who would have died from pneumococcal pneumonia had a delay of two or three years been imposed on the introduction of sulphapyridine (M & B 693) .
The British alternative to the FDA is now proposed in the Bill before Parliament. In the White Paper introducing it the Minister of Health gave an assurance that his aim would be to maintain the flexibility and the exercise of professional responsibility which the experience of the Safety of Drugs Committee had shown to be necessary.
Nevertheless, it is not easy to introduce flexibility and informality into an Act of Parliament and Ministers of the future may not always have the benign aspirations of Mr Robinson. The intentions of the White Paper were admirable: their interpretation into practice will be the touchstone on which they will be judged; for what is now being laid before Parliament could possibly remove certain essential freedoms in medical care and will certainly increase to some extent the growth of bureaucracy. The Medicines Bill and the Report of the Sainsbury Committee, established by Government to inquire into certain aspects of the pharmaceutical industry, both recommend a Government Licensing Authority to secure the safety and efficacy of medicines and the best conditions for their manufacture, storage, distribution and dispensing. The provisions of the Bill and the recommendations of the Report, however, differ from one another in certain important respects (see Fig 1) .
Though only a very limited number of doctors will have read the Report and still fewer the Bill, I do not expect that this will prevent them from expressing themselves forcibly on the respective merits of the two documents. The Bill and the Report both recommend the setting up of a Medicines Commission to advise, among many other duties, the Government Licensing Authority. In the Bill it is recommended that the Commission should be appointed by the Ministers after consultation with interested organizations and that the staff which the Commission might appoint should be taken into the permanent civil service to protect their security of employment and to ensure their adequate superannuation benefits. The Report, on the other hand, recommrends an independent Commission with powers defined by Statute, with members nominated directly by a variety of organizations without intervention by Ministers and with a staff who should not be civil servants.
In spite of the superficial attraction of the word 'independent' it is probable that the method of appointment of the Commission as envisaged in the Bill is preferable to that in the Report. When the numerous organizations that would claim representation are consideredthe pharmaceutical industry, the Pharmaceutical Society, the dentists, the veterinarians, the homeopaths, the herbalists, the seven Royal Colleges, the British Medical Association, and very likely the pathologists, pxediatricians, dermatologists, anesthetists and psychiatriststhe Commission might become a little unwieldy. Quite apart from that, however, the best way to select a good committee or commission is to ascertain, after full consultation, who are the best men in the country for the required purpose, rather than to concentrate on the organizations to be represented.
The Committee on Safety of Drugs was perhaps a Lilliputian forerunner of the Medicines Commission. Its members were certainly appointed by the Ministerspresumably after taking advicebut none of us feel in consequence that we have become the creatures of the Ministers who incidentally have been invariably helpful and never directive. If they had tried to push us around against our wishes it would have been easy to resign for we are not career civil servants as in the FDA. Again, though our Committee is assisted by a small professional staff of civil servants they remain most valued servants but not, I think, our masters.
It is doubtless salutary that our profession should always regard Ministers with a healthy suspicion, yet this can surely be carried to extremes and a degree of mutual confidence is essential if the National Health Service is to achieve its full potential. I was still a boy when, what seems to most of us now that most necessary measure, the National Insurance Bill of 1911 was introduced, but I can well remember that Lloyd George had a far more bitter struggle with the doctors before the first world war than Aneurin Bevan ever had with us after the second one. The Northcliffe Press then told us that the insurance card with its stampsnow so familiarwas the end of freedom; that the Chancellor of the Exchequer was doing what the worst English Kings had failed to accomplish and what our forefathers would have died to prevent; that mistresses would have inspectors invading their drawingrooms to see if their servants' cards were properly stamped and that servants would immediately be dismissed whenever they became sick. Outside and inside the Albert Hall 20,000 women shrieked 'We won't pay' and 'Taffy was a Welshman, Taffy was a thief'. In the same way we could be unnecessarily apprehensive of the present Medicines Bill.
The Bill envisages a Commission to advise the Minister on broad aspects of policy in regard to medicines and on the setting up of expert committees to prepare the British Pharmacopoeia and to report directly to the Licensing Authority on the subjects with which they are concerned, such, for example, as safety and efficacy, specifications and standards, advertising and promotion, medical devices, veterinary medicines and so forth. The Commission would also act as an appeal tribunal should an appeal be made against any implementation of the Licensing Authority on the advice of an expert committee. The Bill, therefore, regards the Commission not as the ordinary direct source of advice but as an overall planning and appeals body. As such it would probably not have to sit more often than about three or four times a year.
The Report's recommendations, concerned with the licensing of products, in principle follow similar lines to those in the Bill. Nevertheless, it recommends that the Commission itself should tender advice to the Licensing Authority; the expert committees would thus be sub-committees whose advice would be channelled to the Authority through the Commission and subject to its review and modification in the process. Thus, the Report recommends investing the Commission with wide responsibilities and powers. Its broad functions, determined by statute within which it would be free to extend and develop its operations, would include advice on licensing, the direction of the work of its sub-committees, the preparation of the pharmacopoeia, the detailed control of advertising, the regulation of clinical trials, the classification of medicines and an examination of prices.
It is apparent that the Bill gives ultimate power to the Minister acting on professional advice, whereas the Report gives it to the accredited representatives of professional organizations. On the other hand, the Minister is responsible to Pailiament and subject to the sanctions of the hustings. As far as I can see the Commission ofthe Report is responsible to no one and its decisions would not be subject to appeal, and 'Power without responsibility', as Stanley Baldwin once rather surprisingly said, 'is the prerogative of the harlot throughout the ages.'
Finally, and perhaps most importantly, the question arises as to whether any single body could effectively undertake the functions of the Commission as recommended by the Sainsbury Committee or secure the confidence and support of the many organizations affected by its activities. When I recall how often, with the relatively few responsibilities of the Safety of Drugs Committee, one has to travel to London, it is difficult to believe that the commitments suggested for the Commission in the Report could be successfully accomplished save by a number of retired men living in London in practically continuous session. It is also questionable whether they would be able to secure first-class experts for their subcommittees to work in circumstances in which their advice was always subject to review and modification before it reached the Licensing Authority. Such a Commission might well become authoritarian and in due course could profoundly influence or even determine the practice of therapeutics in this country; and medical establishments -Aristotle and Galen for example have not always been in the van of progress. Perhaps the Minister, properly advised, might only chastise us with little whips, whereas the superannuated sodality which I have perhaps dreamed up of cockney medical, pharmaceutical, veterinary and dental Solons might chastise us with scorpions. I sometimes envy these people with strong principles and convictions who, confronted by any controversial problem, immediately seem to know what is right and what is wrong. They are the people who do most good in the worldand the most harm. I am not one of them for, as I get older, I seem to find the answer to most controversial questions more and more difficult: there always seems to be so much to be said on both sides. Nevertheless, a proper understanding of the problems involved is the first stage to their intelligent solution.
